The Incidence and Predictors of Solid- and Hematological Malignancies in Patients with Giant Cell Arteritis: A Large Real-World Database Study

Lior Dar 1,2,*,†, Niv Ben-Shabat 1,2,†, Shmuel Tiosano 1,2,‡, Abdulla Watad 1,2,3,‡, Dennis McGonagle 3, Doron Komaneshter 4, Arnon Cohen 4,5, Nicola Luigi Bragazzi 6,† and Howard Amital 1,2,‡

1 Department of Medicine ‘B’, The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan 5265601, Israel; nivben7@gmail.com (N.B.-S.); shmil.t@gmail.com (S.T.); watad.abdulla@gmail.com (A.W.); Howard.Amital@sheba.health.gov.il (H.A.)
2 Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel
3 Section of Musculoskeletal Diseases, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK; D.G.McGonagle@leeds.ac.uk
4 Chief Physician’s Office, Clalit Health Services, Tel-Aviv 6209813, Israel; doronko1@clalit.org.il (D.K.); arcohen@clalit.org.il (A.C.)
5 Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
6 Laboratory for Industrial and Applied Mathematics (LIAM), York University, Toronto, ON M3J 1P3, Canada; robertobragazzi@gmail.com
* Correspondence: Lior.Dar@sheba.health.gov.il; Tel.: +972-3-5302435; Fax: +972-3-5302638
† Equal contribution.
‡ Equal contribution.

Abstract: Background: The association between giant cell arteritis (GCA) and malignancies had been widely investigated with studies reporting conflicting results. Therefore, in this study, we aimed to investigate this association using a large nationwide electronic database. Methods: This study was designed as a retrospective cohort study including GCA patients first diagnosed between 2002–2017 and age, sex and enrollment time-matched controls. Follow-up began at the date of first GCA-diagnosis and continued until first diagnosis of malignancy, death or end of study follow-up. Results: The study enrolled 7213 GCA patients and 32,987 age- and sex-matched controls. The mean age of GCA diagnosis was 72.3 (SD 9.9) years and 69.1% were women. During the follow-up period, 659 (9.1%) of GCA patients were diagnosed with solid malignancies and 144 (2.0%) were diagnosed with hematologic malignancies. In cox-multivariate-analysis the risk of solid malignancies (HR = 1.12 [95%CI: 1.02–1.22]), specifically renal neoplasms (HR = 1.60 [95%CI: 1.15–2.23]) and sarcomas (HR = 2.14 [95%CI: 1.41–3.24]), and the risk of hematologic malignancies (HR = 2.02 [95%CI: 1.66–2.47]), specifically acute leukemias (HR = 1.81 [95%CI: 1.06–3.07]), chronic leukemias (HR = 1.82 [95%CI: 1.19–2.77]), Hodgkin’s lymphomas (HR = 2.42 [95%CI: 1.12–5.20]), non-Hodgkin’s lymphomas (HR = 1.66: [95%CI 1.21–2.29]) and multiple myeloma(HR = 2.40 [95%CI: 1.63–3.53]) were significantly increased in GCA patients compared to controls. Older age at GCA-diagnosis (HR = 1.36 [95%CI: 1.25–1.47]), male-gender (HR = 1.46 [95%CI: 1.24–1.72]), smoking (HR = 1.25 [95%CI: 1.04–1.51]) and medium-high socioeconomical status (HR = 1.27 [95%CI: 1.07–1.50]) were independently associated with solid malignancy while age (HR = 1.47 [95%CI: 1.22–1.77]) and male-gender (HR = 1.61 [95%CI: 1.14–2.29]) alone were independently associated with hematologic- malignances. Conclusion: our study demonstrated higher incidence of hematologic and solid malignancies in GCA patients. Specifically, leukemia, lymphoma, multiple myeloma, kidney malignancies, and sarcomas. Age and male gender were independent risk factors for hematologic malignancies among GCA patients, while for solid malignancies, smoking and SES were risk factors as well.

Keywords: giant cell arteritis; temporal arteritis; vasculitis; autoinflammation; malignancy
1. Introduction

Giant cell arteritis (GCA) is an inflammatory disorder of large and medium-sized arteries that preferentially involves branches of the external carotid artery [1]. Epidemiologic studies demonstrated disease predominance among elderly females and individuals of Northern European ancestry. The etiopathogenesis of GCA is uncertain, with evidence suggesting roles played by certain genetic backgrounds as well as immunosenescence as driving forces in the disease pathogenesis [2,3]. The association between chronic inflammation and tumorigenesis had been widely investigated. Over the years, various shared mechanisms were postulated to be at the core of both phenomena such as excessive cell replication, resistance to growth inhibition, and enhanced angiogenesis [4,5].

Several rheumatologic diseases were associated with increased risk of malignancy. The association between Sjogren’s syndrome, rheumatoid arthritis (RA) and systemic sclerosis with malignancy had been widely established by previous studies. RA and Sjogren’s syndrome were found to be associated particularly with lymphomas, whereas systemic sclerosis patients were associated with lung cancer [6–10]. The results between systemic lupus erythematosus (SLE) and malignancy were less equivocal [11–13]. Regarding vasculitides, polyarteritis nodosa, and antineutrophil cytoplasmic antibody (ANCA) associated vasculitis were shown to have a positive association with malignancies, predominantly of hematologic origin [14–16].

Data regarding the association between GCA and the occurrence of malignancies has furnished conflicting results. Several studies had found no significant association [17–20], while others had shown positive association between GCA and the incidence of malignancy [21–23], including a recent meta-analysis [24]. The above-mentioned meta-analysis demonstrated a 14% excess risk of malignancy compared with non-GCA/PMR participants. Among the few studies that addressed specific types of cancers, higher rates of solid tumors (melanoma, stomach, lung, prostate, kidney, nervous system, and endocrine malignancies) as well as non-Hodgkin’s lymphoma (NHL), multiple myeloma, and leukemia among GCA patients were reported [23,25]. While breast, endometrial, and gastrointestinal tract malignancies were reported to be at significantly lower rates in these patients [23,25].

Dysphagia, anemia, and an abnormal temporal artery on palpation at the time of GCA diagnosis were found to be associated with the incidence of malignancy [20]. However, most of these studies had relatively small cohorts. Among the two studies with large cohorts, the first did not directly address this issue and did not investigate different types of cancer [26], while the other lacked a comparison cohort and used the general population cancer rates as a reference [23]. Furthermore, no study so far had investigated the potential effect of socioeconomic status (SES), obesity and smoking, which are known to be related to malignancies and may act as potential confounders.

Therefore, in this study, we investigated the relation between GCA and malignancy in a large population-based cohort, considering, for the first time, potential demographic parameters in a multivariate model.

2. Materials and Methods

2.1. Data Source

This study was approved by the CHS Ethics Committee in Tel Aviv, Israel. Approval number 0212-17-COM. No informed consent was needed (existing database). For this study, we used Clalit Healthcare Services (CHS) electronic database. CHS is the largest health maintenance organization (HMO) in Israel and serves approximately 4.5 million members, which comprises over 50% of the Israel population. Data in CHS database is collected continuously from pharmaceutical, medical, and administrative operating systems, and is going through a process of diagnosis validation by logistic checks. The CHS database was shown to have high validity in previous studies, including those involving diagnoses from rheumatology [27–30] and oncology [31] disciplines. Moreover, the current cohort of GCA patients was used by our group in a recent study addressing mortality in GCA [32].
2.2. Study Population and Design

This study was designed as a retrospective cohort study comparing incident GCA cases to age- and sex-matched controls. Our GCA cohort included all patients with at least one documented diagnosis of GCA (ICD9 code 446.5) made in primary care centers, inpatients and outpatient clinics, or hospitalization discharge letters, between 1 January 2002 to 31 December 2017. Patients that were under the age of 50 years at the time of the first diagnosis and patients who had a recorded diagnosis of GCA before 1 January 2002 were excluded. Controls were age, gender, and enrollment date-matched and included patients without a diagnosis of GCA that were randomly assigned from the CHS electronic database in a ratio of about 5:1. Follow-up began at the date of first GCA diagnosis and continued until the earliest of the following: occurrence of malignancy, death or end of study follow-up on 1 September 2018.

2.3. Study Variables

The definition of a malignancy was based on a documented diagnosis of that type of malignancy in the medical records, as registered in the CHS database. Based on date of first diagnosis, malignancies were categorized as occurring before GCA diagnosis (enrollment time for controls) or after. Malignancies that were diagnosed before the occurrence of GCA (including those diagnosed before 2002), were addressed as baseline malignancies, while those that were diagnosed during follow-up (after the occurrence of GCA) were addressed as incident malignancies.

For each subject, age, gender and socioeconomic status (SES) at enrollment time were obtained. SES was defined according to a poverty index which is based on the member’s residence area. The poverty index was defined during the 2008 National Census, and considered average household income, education, crowding, and car ownership. We divided the population into three categories based on terciles. Obesity was considered as having a Body-Mass-Index $\geq 30$ kg/m$^2$ in a measure during the year of enrollment. Smoking was dichotomized into ever vs. never smoked at the time of enrollment. All data were obtained from the CHS electronic database, which was previously demonstrated to have 90 to 100% degree of accuracy [27].

2.4. Statistical Analysis

Differences in baseline characteristics between different groups of independent variables were compared using t-test or Mann–Whitney U test for continuous variables, and $\chi^2$ test for categorical variables. Rates of malignancies were compared between GCA patients and controls in three time periods: at any time during subject life period, before the diagnosis of GCA/enrollment and after the diagnosis of GCA/enrollment. Survival analysis demonstrating cancer-free cumulative frequency was performed using Kaplan–Meier method with a post hoc log-rank comparison of GCA patients and controls. Cox proportional hazard model was used for univariate and multivariate survival analyses. Malignancy was considered as an event, and hazard ratios (HR) were calculated comparing GCA and controls. This analysis included only patients without diagnosis of malignancy before enrollment. The multivariate model accounted for age, gender, smoking, SES, and obesity. Patients with a diagnosis of any malignancy before enrollment were excluded from survival analyses. Statistical analysis was performed using the commercial software “Statistical Package for the Social Sciences” (SPSS for Windows, V.23.0 (IBM SPSS Statistics, Armonk, NY, USA).

3. Results

3.1. Cohort Characteristics

The study population included 7213 GCA patients and 32,987 age- and sex-matched controls. The mean age of GCA diagnosis was 72.3 $\pm$ 9.9 years (median 73.1 years) and 69.1% were women. No statistically significant difference was found in SES between
groups. The GCA patients had significantly higher rates of smoking (24.8% vs. 19.8%, \( p < 0.001 \)) and obesity (24.2% vs. 16.3%, \( p < 0.001 \)) than controls (Table 1).

### Table 1. Basic characteristics of the study population.

| Characteristic                  | GCA (\( n = 7213 \)) | Controls (\( n = 32,987 \)) | \( p \)-Value |
|--------------------------------|------------------------|-----------------------------|---------------|
| Age, mean ± SD; median         | 72.3 ± 9.9; 73.1       | 72.1 ± 9.8; 73.1            | 0.16          |
| Gender (females), n (%)        | 4987 (69.1%)           | 22,929 (69.5%)              | 0.53          |
| Follow-up duration (years)     | 7.1 ± 4.4; 6.5         | 7.4 ± 4.4; 6.9              | <0.001        |
| SES, n (%)                     | 2368 (33.1%)           | 11,091 (33.0%)              | 0.72          |
| Smoking, n (%)                 | 1790 (24.8%)           | 7005 (21.2%)                | <0.001        |
| Obesity, n (%)                 | 1747 (24.2%)           | 6949 (21.1%)                | <0.001        |
| Death, n (%)                   | 2425 (33.6%)           | 10,481 (31.8%)              | <0.01         |

GCA, giant cell arteritis; SD, standard-deviation; SES, socioeconomic status. \( a \) Available for 99.2% of data.

### 3.2. Cancer Rates in GCA Patients

Baseline rates of hematologic cancers (1.9% vs. 1.2%, \( p < 0.001 \)) specifically, multiple myeloma (0.4% vs. 0.2%, \( p < 0.001 \)), non-Hodgkin's lymphoma (0.9% vs. 0.6%, \( p < 0.001 \)), and Hodgkin's lymphoma (0.3% vs. 0.1%, \(<0.005\)), as well as prostate cancer (5.5% vs. 4.4%, \( p < 0.05 \)), were significantly higher in GCA patients compared to controls. During follow-up 659 (9.1%) of GCA patients were diagnosed with solid cancer and 144 (2.0%) were diagnosed with hematologic cancer. Regarding cancers first diagnosed after enrollment (incident cases), rates of solid cancers (9.1% vs. 8.4%, \( p < 0.05 \)), specifically kidney (0.7% vs. 0.4%; \( p < 0.05 \)) and sarcoma (0.4% vs. 0.2%; \( p < 0.001 \)) and rates of hematologic cancers (2% vs. 1%, \( p < 0.001 \)), specifically acute-leukemia (0.3% vs. 0.1%; \( p < 0.05 \)), chronic leukemia (0.4% vs. 0.2%; \( p < 0.05 \)), multiple myeloma (0.5% vs. 0.2%; \( p < 0.001 \)), non-Hodgkin's lymphoma (0.7% vs. 0.4%; \( p < 0.005 \)), and Hodgkin's lymphoma (0.2% vs. 0.1%; \( p < 0.05 \)) were higher in GCA patients compared to controls (Table 2). Rates of CNS, bone, larynx, and pancreas malignancies were also examined and were comparable for GCA and controls (data not shown).

### Table 2. Malignancy rates by site, relative to the time of GCA diagnosis, or enrollment time for controls.

| Cancer Site       | GCA (\( n = 7213 \)) n (%) | Controls (\( n = 32,987 \)) n (%) | \( p \)-Value |
|-------------------|-----------------------------|------------------------------------|---------------|
| Solid cancers     | 1378 (19.1%)                | 6115 (18.5%)                       | 0.26          |
| Before diagnosis/enrollment | 798 (11.1%)                | 3634 (11%)                        | 0.91          |
| After diagnosis/enrollment | 659 (9.1%)                | 2765 (8.4%)                       | <0.05         |
| Oropharynxal      | 47 (0.7%)                   | 221 (0.7%)                        | 0.93          |
| Before diagnosis/enrollment | 7 (0.1%)                   | 25 (0.1%)                         | 0.49          |
| After diagnosis/enrollment | 40 (0.6%)                   | 196 (0.6%)                        | 0.73          |
| Thyroid           | 63 (0.9%)                   | 233 (0.7%)                        | 0.14          |
| Before diagnosis/enrollment | 49 (0.7%)                   | 177 (0.5%)                        | 0.14          |
| After diagnosis/enrollment | 14 (0.2%)                   | 56 (0.2%)                         | 0.64          |
| Lung              | 115 (1.6%)                  | 484 (1.5%)                        | 0.42          |
Table 2. Cont.

| Cancer Site               | GCA ($n = 7213$) n (%) | Controls ($n = 32,987$) n (%) | $p$-Value |
|---------------------------|------------------------|-------------------------------|-----------|
| Before diagnosis/enrollment | 24 (0.3%)             | 152 (0.5%)                    | 0.17      |
| After diagnosis/enrollment | 91 (1.3%)             | 332 (1.0%)                    | 0.054     |
| Esophagus                 | 13 (0.2%)              | 43 (0.1%)                     | 0.29      |
| Before diagnosis/enrollment | 2 (0%)                | 15 (0%)                       | 0.75      |
| After diagnosis/enrollment | 11 (0.2%)             | 28 (0.1%)                     | 0.09      |
| Stomach                   | 40 (0.6%)              | 238 (0.7%)                    | 0.14      |
| Before diagnosis/enrollment | 20 (0.3%)             | 92 (0.3%)                     | 0.99      |
| After diagnosis/enrollment | 20 (0.3%)             | 146 (0.4%)                    | 0.058     |
| Colorectal                | 286 (4.1%)             | 1368 (4.0%)                   | 0.49      |
| Before diagnosis/enrollment | 151 (2.1%)            | 802 (2.4%)                    | 0.10      |
| After diagnosis/enrollment | 135 (1.9%)            | 566 (1.7%)                    | 0.37      |
| Liver and bile ducts     | 33 (0.5%)              | 132 (0.4%)                    | 0.48      |
| Before diagnosis/enrollment | 6 (0.1%)              | 17 (0.1%)                     | 0.28      |
| After diagnosis/enrollment | 27 (0.4%)             | 115 (0.3%)                    | 0.75      |
| Kidney                    | 79 (1.1%)              | 306 (0.9%)                    | 0.18      |
| Before diagnosis/enrollment | 32 (0.4%)             | 167 (0.5%)                    | 0.57      |
| After diagnosis/enrollment | 47 (0.7%)             | 139 (0.4%)                    | <0.05     |
| Bladder                   | 134 (1.9%)             | 554 (1.7%)                    | 0.29      |
| Before diagnosis/enrollment | 66 (0.9%)             | 281 (0.9%)                    | 0.58      |
| After diagnosis/enrollment | 68 (0.9%)             | 273 (0.8%)                    | 0.32      |
| Breast *                  | 365 (7.3%)             | 1810 (7.9%)                   | 0.18      |
| Before diagnosis/enrollment | 260 (5.2%)            | 1275 (5.6%)                   | 0.35      |
| After diagnosis/enrollment | 105 (2.1%)            | 537 (2.3%)                    | 0.35      |
| Uterus *                  | 56 (1.1%)              | 313 (1.4%)                    | 0.19      |
| Before diagnosis/enrollment | 31 (0.6%)             | 175 (0.8%)                    | 0.32      |
| After diagnosis/enrollment | 25 (0.5%)             | 138 (0.6%)                    | 0.47      |
| Cervix *                  | 14 (0.3%)              | 80 (0.3%)                     | 0.49      |
| Before diagnosis/enrollment | 11 (0.2%)             | 49 (0.2%)                     | 0.87      |
| After diagnosis/enrollment | 3 (0.1%)              | 31 (0.1%)                     | 0.26      |
| Ovary *                   | 32 (0.6%)              | 158 (0.7%)                    | 0.77      |
| Before diagnosis/enrollment | 12 (0.2%)             | 70 (0.3%)                     | 0.55      |
| After diagnosis/enrollment | 20 (0.4%)             | 88 (0.4%)                     | 0.81      |
| Prostate b                | 177 (8.0%)             | 695 (6.9%)                    | 0.09      |
| Before diagnosis/enrollment | 122 (5.5%)            | 445 (4.4%)                    | <0.05     |
| After diagnosis/enrollment | 55 (2.5%)             | 250 (2.5%)                    | 0.99      |
| Sarcoma                   | 58 (0.8%)              | 170 (0.5%)                    | <0.01     |
| Before diagnosis/enrollment | 26 (0.4%)             | 97 (0.3%)                     | 0.35      |
| After diagnosis/enrollment | 32 (0.4%)             | 73 (0.2%)                     | <0.001    |
| Melanoma                  | 101 (1.4%)             | 433 (1.3%)                    | 0.57      |
| Before diagnosis/enrollment | 59 (0.8%)             | 251 (0.8%)                    | 0.61      |
| After diagnosis/enrollment | 42 (0.6%)             | 182 (0.6%)                    | 0.73      |
| Hematologic cancers       | 274 (3.8%)             | 704 (2.1%)                    | <0.001    |
| Before diagnosis/enrollment | 137 (1.9%)            | 380 (1.2%)                    | <0.001    |
| After diagnosis/enrollment | 144 (2.0%)            | 345 (1.0%)                    | <0.001    |
| Acute Leukemia            | 36 (0.5%)              | 96 (0.3%)                     | <0.005    |
| Before diagnosis/enrollment | 16 (0.2%)             | 47 (0.1%)                     | 0.14      |
| After diagnosis/enrollment | 20 (0.3%)             | 49 (0.1%)                     | <0.05     |
Table 2. Cont.

| Cancer Site                             | GCA (n = 7213) n (%) | Controls (n = 32,987) n (%) | p-Value |
|-----------------------------------------|----------------------|-----------------------------|---------|
| Chronic Leukemia                        | 55 (0.8%)            | 153 (0.5%)                  | <0.01   |
| Before diagnosis/enrollment             | 21 (0.3%)            | 74 (0.2%)                   | 0.29    |
| After diagnosis/enrollment              | 32 (0.4%)            | 79 (0.2%)                   | <0.01   |
| Myelodysplastic syndrome                | 26 (0.4%)            | 68 (0.2%)                   | <0.05   |
| Before diagnosis/enrollment             | 14 (0.2%)            | 37 (0.1%)                   | 0.10    |
| After diagnosis/enrollment              | 12 (0.2%)            | 31 (0.1%)                   | 0.11    |
| Multiple Myeloma                        | 71 (1%)              | 135 (0.4%)                  | <0.001  |
| Before diagnosis/enrollment             | 29 (0.4%)            | 59 (0.2%)                   | <0.001  |
| After diagnosis/enrollment              | 39 (0.5%)            | 76 (0.2%)                   | <0.001  |
| Non-Hodgkin Lymphoma                    | 121 (1.7%)           | 325 (1%)                    | <0.001  |
| Before diagnosis/enrollment             | 68 (0.9%)            | 182 (0.6%)                  | <0.001  |
| After diagnosis/enrollment              | 52 (0.7%)            | 143 (0.4%)                  | <0.005  |
| Hodgkin Lymphoma                        | 32 (0.4%)            | 64 (0.2%)                   | <0.001  |
| Before diagnosis/enrollment             | 21 (0.3%)            | 45 (0.1%)                   | <0.005  |
| After diagnosis/enrollment              | 11 (0.2%)            | 19 (0.1%)                   | <0.05   |

Abbreviations: GCA, giant cell arteritis; a for female patients b for male patients.

3.3. Cancer Risk in GCA Patients

At the univariate cox model, GCA patients significantly demonstrated increased risk of solid cancers in general (HR 1.13 [95%CI 1.03–1.23]), specifically lung cancer (HR 1.30 [95%CI 1.03–1.64]), kidney cancer (HR 1.62 [95%CI 1.16–2.25]) and sarcomas (HR 2.10 [95%CI 1.38–3.17]), as well as increased risk of overall hematological malignancies (HR 1.62 [95%CI 1.16–2.25]) and more specifically acute leukemia (HR 1.94 [95%CI 1.15–3.26]), chronic leukemia (HR 1.94 [95%CI 1.29–1.92]), Hodgkin’s lymphoma (HR 2.75 [95%CI 1.31–5.78]), non-Hodgkin’s lymphoma (HR 1.73 [95%CI 1.26–2.38]), and multiple myeloma (HR 2.44 [95%CI 1.67–3.59]) compared to controls (Table 3). At the cox multivariate model, adjusting for age, sex, SES, obesity and smoking status, GCA patients demonstrated significantly increased risk of solid cancers in general (HR 1.12 [95%CI 1.02–1.22]), specifically renal cancer (HR 1.60 [95%CI 1.15–2.23]) and sarcomas (HR 2.14 [95%CI 1.41–3.24]), as well as increased risk of hematologic cancers in general (HR 2.02 [95%CI 1.66–2.47]), specifically acute leukemia (HR 1.81 [95%CI 1.06–3.07]), chronic leukemia (HR 1.82 [95%CI 1.19–2.77]), Hodgkin’s lymphoma (HR 2.42 [95%CI 1.12–5.20]), non-Hodgkin’s lymphoma (HR 1.66 [95%CI 1.21–2.29]), and multiple myeloma (HR 2.40 [95%CI 1.63–3.53]). The risk of gastric cancer (HR 0.61 [95%CI 0.37–0.98]) was significantly lower in GCA patients compared to controls (Table 3).

Table 3. Hazard ratios for the incidence of cancer in GCA patients compared to age- and sex-matched controls.

| Cancer Site      | Time (Months) to Malignancy Mean (SD) | Crude HR | Adjusted b HR |
|------------------|--------------------------------------|----------|----------------|
|                  |                                      | HR 95%CI | HR 95%CI       |
| Solid cancers *  |                                      | 50.8 (40)| 1.13, 1.23     | 1.12, 1.22 |
| Oropharyngeal    |                                      | 52.1 (33)| 0.88, 0.69, 1.37 | 0.96, 0.69, 1.35 |
| Thyroid          |                                      | 44.7 (41)| 1.19, 0.66, 2.14 | 1.20, 0.66, 2.16 |
| Lung             |                                      | 49.1 (39)| 1.30, 1.03, 1.64 | 1.26, 0.99, 1.59 |
Table 3. Cont.

| Cancer Site                  | Time (Months) to Malignancy * Mean (SD) | Crude HR | Adjusted b HR |
|------------------------------|----------------------------------------|----------|---------------|
| Esophagus                    | 47.9 (31)                              | 1.86     | 0.93, 3.74    |
| Stomach                      | 51.4 (43)                              | 0.65     | 0.41, 1.04    |
| Colorectal                   | 43.9 (35)                              | 1.13     | 0.94, 1.37    |
| Liver and bile ducts         | 51.3 (39)                              | 1.12     | 0.73, 1.69    |
| Kidney                       | 45.4 (40)                              | 1.62     | 1.16, 2.25    |
| Bladder                      | 63.4 (42.7)                            | 1.18     | 0.91, 1.54    |
| Breast                       | 58 (42)                                | 0.93     | 0.75, 1.14    |
| Uterus                       | 73.9 (47)                              | 0.86     | 0.56, 1.31    |
| Cervix                       | 45.5 (62)                              | 0.46     | 0.14, 1.50    |
| Ovary                        | 63.2 (57)                              | 1.08     | 0.66, 1.76    |
| Prostate                     | 50.3 (38)                              | 1.07     | 0.79, 1.43    |
| Sarcoma                      | 46.5 (43)                              | 2.10     | 1.38, 3.17    |
| Melanoma                     | 56 (39)                                | 1.10     | 0.78, 1.53    |
| Hematologic cancers          | 49.4 (46)                              | 2.02     | 1.66, 2.47    |
| Acute Leukemia               | 55 (56)                                | 1.94     | 1.15, 3.26    |
| Chronic Leukemia             | 71.3 (51)                              | 1.94     | 1.29, 1.92    |
| Myelodysplastic syndrome     | 36.3 (26)                              | 1.83     | 0.94, 3.35    |
| Hodgkin Lymphoma             | 40 (43)                                | 2.75     | 1.31, 5.78    |
| Non-Hodgkin Lymphoma         | 49.1 (41)                              | 1.73     | 1.26, 2.38    |
| Multiple Myeloma             | 41.2 (44)                              | 2.44     | 1.67, 3.59    |

Abbreviations: CI, confidence interval; HR, hazard ratio; SD, standard deviation. * Among GCA patients with no prior malignancy; b The model included the variables: age, gender, socioeconomic status, smoking, and obesity; c Only females were included in the model; d Only males were included in the model. * Statistical significance at 95% confidence level. ** Statistical significance at 99% confidence level.

Kaplan–Meier survival curves, assessing cumulative cancer-free survival (Figure 1) demonstrate survival curves for GCA patients in both solid (Figure 1A) and hematologic (Figure 1B) cancers. The average time (mean [months] ± SD) to the diagnosis of any malignancy was significantly shorter in GCA patients (48.6 ± 41.3) compared to controls (58.1 ± 43.6; p < 0.001).
3.4. Predictors of Cancer in GCA Patients

Older age at diagnosis of GCA (HR 1.36 [95%CI 1.25–1.47], for every 10 years), male gender (HR 1.46 [95%CI 1.24–1.72]), smoking (HR 1.25 [95%CI 1.04–1.51]) and medium-high SES (HR 1.27 [95%CI 1.07–1.50]) were independent risk factors for solid cancers in a multivariate analysis. For hematological cancers, only older age at diagnosis (HR 1.66 [95%CI 1.21–2.29]) and male gender (HR 1.66 [95%CI 1.21–2.29]) were significant predictors (Table 4).

Table 4. Independent predictors for solid and hematologic malignancies in GCA cohort.

| HR (95%CI) | Solid Cancers | Hematologic Cancers |
|------------|---------------|---------------------|
| Age at diagnosis (every 10 years increment) | 1.36 (1.25–1.47) ** | 1.47 (1.22–1.77) ** |
| Gender (males vs. females) | 1.46 (1.24–1.72) ** | 1.61 (1.14–2.29) ** |
| Smoking (ever vs. never) | 1.25 (1.04–1.51) * | 1.27 (0.85–1.90) |
| Obesity (BMI > 30 kg/m² vs. normal) | 1.14 (0.94–1.38) | 1.14 (0.75–1.73) |
| SES (high and medium vs. low) | 1.27 (1.07–1.50) ** | 1.25 (0.86–1.82) |

Abbreviations: CI, confidence interval; HR, hazard ratio; BMI, body mass index; SES, socioeconomic status. * The model included the variables: age, gender, socioeconomic status, smoking, and obesity. ** Statistical significance at 95% confidence level. *** Statistical significance at 99% confidence level.

4. Discussion

In this large nationwide population-based study, we found an increased risk for sarcomas, kidney malignancies, and overall solid malignancies in GCA patients compared to controls. GCA was also separately associated with an increased risk of all hematologic malignancies, (leukemia, lymphoma, and multiple myeloma). The GCA cohort in our study is consistent in terms of age of diagnosis and female to male ratio with previous reports [33]. Malignancy rates were also appropriate for age [34].
The increased risk for hematologic, sarcoma, and kidney malignancies seen in our study corresponds with several large scale studies [22–24]. Most notably is the study of Sundquist et al. [23], which encompassed 36,000 GCA cases with concurrent polymyalgia rheumatica from a Swedish registry. Similar to our results, Sundquist et al. [23] reported increased risk of hematologic malignancies with a standardized incidence ratio (SIR) ranging from 1.32 to 2.69, renal malignancies with a SIR of 1.56, and sarcomas with a SIR of 4.92 (mainly in the first year after GCA diagnosis). Higher rates of lung malignancies were also reported in the Swedish report, which is comparable with our results of the unadjusted model; however, after adjusting these results to smoking, which was more common in GCA patients, these results were no longer statistically significant. Unlike our study, Sundquist et al. [23] did not use a matched comparison cohort and included only hospitalized patients. Another interesting finding of our study is the decreased risk for gastric cancer seen in GCA patients. This association was previously reported by Stamatis et al. [25], which hypothesized that obesity could act as a confounder in this case due to its known association with gastric cancer. However, this association was demonstrated in our study after an adjustment to obesity. Therefore, it is unlikely to be the cause. Further inquiry is required in order to clarify this untrivial association.

In our GCA cohort older age at diagnosis and male gender were predictors of both solid and hematological malignancies, while smoking and medium-high socioeconomic status were significant predictors only for solid malignancies. These results are rather consistent with risk factors for malignancy in the general population, and we were the first to exhibit them in GCA patients [35,36].

There is no well-formulated theory explaining this linkage tying an increased rate of malignancies with coexisting GCA. Various reports had highlighted the role of ongoing inflammation as a driving force in the pathogenesis and progression of malignancies. For example, Craver et al. [37] investigated the role of inflammation in myeloid line dysregulation and malignancies, and noted that chronic inflammation may promote hematopoietic stem cell exhaustion, promoting the emergence of mutant clones thus promoting the development of myeloid malignancy [37]. Moreover, they reported that higher concentrations of serum inflammatory cytokines in myeloid malignancies, which were shown to be associated with disease initiation, burden, and progression, as well as worsened survival outcome [37].

Smedby et al. [38] conducted a large population-based case-controlled study that demonstrated the increased risk of NHL in patients with certain autoimmune/inflammatory disease (RA, Sjogren’s syndrome, SLE and celiac disease), and Baecklund et al. [39] postulated that the chronic B-cell stimulation and antigenic drive play a role in inflammation-related lymphogenesis. Moreover, systemic autoimmune features, such as increased resistance to apoptosis, were reported to further enhance the carcinogenic effects of B cell proliferation [40]. As for kidney cancer, an association between malignancy and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis had been previously demonstrated, and in particular, renal carcinoma was found to be associated with granulomatosis with polyangiitis (Wegener’s granulomatosis), suggesting a carcinogenic effect of the disease process itself and chronic stimulation of the immune system and perhaps the result of exposure to alkylating agents [14,15]. There might be a common pathogenetic pathway that leads to both GCA and kidney cancer, probably via the involvement of the renal vasculature.

Another possible explanation for the increased risk of hematologic malignancies and GCA can be a shared trigger for both conditions. Several studies have suggested a role for environmental factors, such as viral genome integration by oncogenic viruses (EBV, HTLV-1, HHV-8), which has been associated with the pathogenesis of specific NHL subtypes [41]. Moreover, various microbe and viral sequences, including varicella zoster virus, have been detected in temporal artery lesions [42]. There may be a shared trigger for GCA and hematologic malignancies that has yet to be discovered.

A setting of close temporal association with the onset of GCA may represent a paraneoplastic syndrome triggered by the anti-tumor immune response [43]. This mechanism is
reinforced by a study demonstrated a correlation between vasculitis disease activity to the onset, resolution, and recurrence of solid tumors [44].

Our investigation has several strengths; the population-based design, which is based on big data analysis of real-life populations. Moreover, the large database ensures the inclusion and representation of the whole population, thereby facilitating generalization and avoiding referral bias. However, various limitations warrant consideration. First, we had no data regarding temporal-artery biopsies, which is the gold-standard of GCA diagnosis. Thus, we were unable to distinguish those diagnosed based on pathology from those diagnosed based on laboratory, imaging, and clinical findings. However, it is worth noting that that temporal biopsy is not mandatory for the diagnosis of GCA, which can be clinically done with the presence of three out of five criteria. Furthermore, previous studies showed the same features and outcomes in biopsy-proven GCA patients compared to those diagnosed clinically [20,24,25]. Regarding the ascertainment of cancer diagnosis and co-morbidities, our cohort had similar rates to those reported by the Israeli ministry of health [34] and smoking and obesity rates matched those of the Israeli population of the same age [45,46]. In addition, our data were limited regarding the use of systemic corticosteroids and other immunosuppressants commonly used for the treatment of GCA patients. Corticosteroids is the cornerstone in the treatment of GCA, and all patients with GCA are advised to start with corticosteroids treatment [47]. In earlier studies, corticosteroids therapy was linked to NHL, yet more recent ones did not confirm this observation NHL [11,38,48]. Moreover, our study investigated the incidence of malignancy in GCA patients, and did not investigate malignancy as a cause of death in GCA patients, as was sown in a previous large recent study [49] to be lower in GCA patients. The latter result of decreased risk of death due to cancer in GCA patients can be explained by an increased cardiovascular death risk. Finally, detection bias cannot be ruled out, as GCA diagnosed patients may be exposed to higher rates of physician and imaging examinations, which may enhance the probability of cancer diagnosis. In addition, we do not have data regarding the use of cyclophosphamide or azathioprine for refractory cases, but if such cases occurred, they are probably extremely rare with negligible effect.

In conclusion, our study demonstrated higher incidence of hematologic and solid malignancies in GCA patients. Specifically, leukemia, lymphoma, multiple myeloma, kidney malignancies and sarcomas. Age and male gender were independent risk factors for hematological malignancies among GCA patients, while for solid malignancies, smoking and SES were risk factors as well.

Author Contributions: Conceptualization, L.D. and H.A.; methodology, N.B.-S.; software, N.B.-S.; validation, A.W.; formal analysis, N.B.-S. and S.T.; investigation, L.D.; resources, D.K.; data curation, A.C.; writing—original draft preparation, L.D.; writing—review and editing, D.M., N.L.B. and A.W.; supervision, H.A.; funding acquisition, S.T. All authors have read and agreed to the published version of the manuscript.

Funding: This article was supported by grants from the Shalvi fund (AW and ST) for medical research and innovation in Israel and from the Israel Cancer Association (ST).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Carmel Medical Center, Israel, (protocol code 0212-17-COM, 04/03/2019).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

GCA: giant cell arteritis, CHS, Clalit Health Services; SES, socioeconomic status; OR, odds ratio; CI, confidence interval; BMI, body mass index; PMR, polymyalgia rheumatica; SIR, standardized incidence ratio; NHL, non-Hodgkin’s lymphoma.

References

1. Salvanes, C.; Cantini, F.; Boiardi, L.; Hunder, G.G. Polymyalgia Rheumatica and Giant-Cell Arteritis. N. Engl. J. Med. 2002, 25, 261–271. [CrossRef]
2. Watts, R.A. 2. Epidemiology of giant cell arteritis: A critical review. Rheumatology 2014, 53, i1–i2. [CrossRef]
3. Watad, A.; Bragazzi, N.L.; Adawi, M.; Amital, H.; Toubi, E.; Porta, B.S.; Shoenfeld, Y. Autoimmunity in the Elderly: Insights from Basic Science and Clinics—A Mini-Review. Gerontology 2017, 63, 515–523. [CrossRef] [PubMed]
4. O’Byrne, K.J.; Dalgleish, A.G. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer 2001, 85, 473–483. [CrossRef] [PubMed]
5. Wang, C.-S.; Sun, C.-F. C-reactive protein and malignancy: Clinico-pathological association and therapeutic implication. Chang. Gung Med. J. 2009, 32, 471–482.
6. Simon, T.A.; Thompson, A.; Gandhi, K.K.; Hochberg, M.C.; Suissa, S. Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis. Arthritis Res. Ther. 2015, 17, 212. [CrossRef] [PubMed]
7. Szekanecz, É.; Szamosi, S.; Horváth, A.; Németh, A.; Juhasz, B.; Szántó, J.; Szűcs, G.; Szekanecz, Z. Malignancies associated with systemic sclerosis. Autoimmun. Rev. 2012, 11, 852–855. [CrossRef] [PubMed]
8. Wang, L.-H.; Wang, W.-M.; Lin, C.-Y.; Lin, S.-H.; Shieh, C.-C. Bidirectional Relationship between Primary Sjögren’s Syndrome and Non-Hodgkin’s Lymphoma: A Nationwide Population-Based Study. J. Rheumatol. 2020, 47, 1374–1378. [CrossRef]
9. Roumm, A.D.; Medsger, T.A.; Jr. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum. 1985, 28, 1336–1340. [CrossRef]
10. Zeineddine, N.; El Khoury, L.; Mosak, J. Systemic Sclerosis and Malignancy: A Review of Current Data. J. Clin. Med. Res. 2018, 10, 625–632. [CrossRef] [PubMed]
11. Bernatsky, S.; Ramsey-Goldman, R.; Clarke, A.E. Malignancy in systemic lupus erythematosus: What have we learned? Best Pract. Res. Clin. Rheumatol. 2009, 23, 539–547. [CrossRef]
12. Sultan, S.M.; Ioannou, Y.; Isenberg, D. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology 2000, 39, 1147–1152. [CrossRef]
13. Myklebust, G.; Wilsgaard, T.; Jacobsen, B.K.; Gran, J.T. No increased frequency of malignant neoplasms in polymyalgia rheumatica. J. Investig. Med. 1998, 46, 217–222. [PubMed]
14. Hill, C.L.; Cole, A.; Rischmueller, M.; Dodd, T.; Coleman, M.; Tucker, G.; Roberts-Thomson, P. Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology 2010, 49, 756–759. [CrossRef]
15. Ješe, R.; Rotar, Ž.; Tomsič, M.; Hočevar, A. Giant Cell Arteritis and Malignancy—More Than Just a Coincidence? JCR J. Clin. Rheumatol. 2018, 24, 85–86. [CrossRef]
16. Wang, L.-H.; Wang, W.-M.; Lin, C.-Y.; Lin, S.-H.; Shieh, C.-C. Bidirectional Relationship between Primary Sjögren’s Syndrome and Non-Hodgkin’s Lymphoma: A Nationwide Population-Based Study. J. Rheumatol. 2020, 47, 1374–1378. [CrossRef] [PubMed]
17. Ješe, R.; Rotar, Ž.; Tomsič, M.; Hočevar, A. Giant Cell Arteritis and Malignancy—More Than Just a Coincidence? JCR J. Clin. Rheumatol. 2018, 24, 85–86. [CrossRef] [PubMed]
18. Haga, H.J.; Eide, G.E.; Brun, J.; Johansen, F. Cancer incidence in a population-based cohort of patients with Wegener’s granulomatosis. Int. J. Cancer 2002, 100, 82–85. [CrossRef]
19. Hasler, P.; Kistler, H.; Gerber, H. Vascularitides in hairy cell leukemia. Semin. Arthritis Rheum. 1995, 25, 134–142. [CrossRef]
20. Myklebust, G.; Wilsaard, G.; Jacobsen, B.K.; Gran, J.T. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. J. Rheumatol. 2000, 29, 2143–2147.
21. Gonzalez-Gay, M.A.; Lopez-Diaz, M.J.; Martinez-Lado, L.; Peña-Sagredo, J.L.; Lopez-Agreda, H.; Miranda-Filloy, J.A.; Gonzalez-Juanatey, C.; Sanchez-Andrade, A.; Martin, J.; Llorca, J. Cancer in Biopsy-Proven Giant Cell Arteritis. A Population-Based Study. Semin. Arthritis Rheum. 2007, 37, 156–163. [CrossRef]
22. Brekke, L.K.; Fevang, B.-T.S.; Diamantopoulos, A.P.; Assmus, J.; Espere, E.; Gjesdal, C.G. Risk of Cancer in 767 Patients with Giant Cell Arteritis in Western Norway: A Retrospective Cohort with Matched Controls. J. Rheumatol. 2019, 47, 722–729. [CrossRef]
23. Haga, H.J.; Eide, G.E.; Brun, J.; Johansen, F. Cancer incidence in a population-based cohort of patients with Wegener’s granulomatosis. Int. J. Cancer 1993, 50, 1335–1339. [PubMed]
24. Ji, J.; Liu, X.; Sundquist, K.; Sundquist, J.; Hemminki, K. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: A follow-up study in Sweden. Rheumatology 2010, 49, 1158–1163. [CrossRef]
25. Ungprasert, P.; Sanguankee, A.; Upala, S.; Knight, E.L. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis. Semin. Arthritis Rheum. 2014, 44, 366–370. [CrossRef]
26. Li, L.; Neogi, T.; Jick, S. Giant cell arteritis and vascular disease—risk factors and outcomes: A cohort study using UK Clinical Practice Research Datalink. Rheumatology 2017, 56, 753–762. [CrossRef] [PubMed]
27. Rennert, G.; Peterburg, Y. Prevalence of selected chronic diseases in Israel. Isr. Med. Assoc. J. IMAJ 2001, 3, 404–408.
28. Bieber, V.; Cohen, A.D.; Freund, T.; Agmon-Levin, N.; Gertel, S.; Amital, H. Autoimmune smoke and fire—coexisting rheumatoid arthritis and chronic obstructive pulmonary disease: A cross-sectional analysis. Immunol. Res. 2013, 56, 261–266. [CrossRef]
29. Zisman, D.; Bitterman, H.; Shalom, G.; Feldhammer, I.; Comanesther, D.; Batat, E.; Greenberg-Dotan, S.; Cohen, S.; Cohen, A.D. Psoriatic arthritis treatment and the risk of herpes zoster. Ann. Rheum. Dis. 2016, 75, 131–135. [CrossRef]
30. Eder, L.; Cohen, A.D.; Feldhammer, I.; Greenberg-Dotan, S.; Batat, E.; Zisman, D. The epidemiology of psoriatic arthritis in Israel—A population-based study. Arthritis Res. 2018, 20, 1–7. [CrossRef] [PubMed]
31. Watad, A.; McGonagle, D.; Bragazzi, N.L.; Tiosano, S.; Comanesther, D.; Shoenfeld, Y.; Cohen, A.D.; Amital, H. Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival. OncolImmunology 2019, 8, e1588084-9. [CrossRef]
32. Ben-Shabat, N.; Tiosano, S.; Shovman, O.; Comanesther, D.; Shoenfeld, Y.; Cohen, A.D.; Amital, H. Mortality among Patients with Giant Cell Arteritis: A Large-scale Population-based Cohort Study. J. Rheumatol. 2019, 47, 1385–1391. [CrossRef] [PubMed]
33. Gonzalez-Gay, M.A.; Rodriguez, T.R.V.; Lopez-Diaz, M.J.; Miranda-Filloy, J.A.; Gonzalez-Juanatey, C.; Martin, J.; Llorca, J. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009, 61, 1454–1461. [CrossRef] [PubMed]
34. Fishler, Y.; Chetrit, A.; Barchana, M.; Modan, B. Completeness of Case Finding in the Israel National Cancer Registry: Methods and Findings; Israel Center for Disease Control: Jerusalem, Israel, 2003.
35. Kane, E.V.; Roman, E.; Cartwright, R.; Parker, J.; Morgan, G. Tobacco and the risk of acute leukaemia in adults. Br. J. Cancer 1999, 81, 1228–1233. [CrossRef] [PubMed]
36. Pasqualetti, P.; Festuccia, V.; Acitelli, P.; Collacciani, A.; Giusti, A.; Casale, R. Tobacco smoking and risk of haematological malignancies in adults: A case-control study. Br. J. Haematol. 1997, 97, 659–662. [CrossRef] [PubMed]
37. Craver, M.B.; El Alaoui, K.; Scherber, M.R.; Fleischman, G.A. The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers 2018, 10, 104. [CrossRef] [PubMed]
38. Smedby, K.E.; Hjalgrim, H.; Asklund, J.; Chang, E.T.; Gregersen, H.; Porwit-MacDonald, A.; Sundström, C.; Åkerman, M.; Melbye, M.; Glimelius, B.; et al. Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype. JNCI J. Natl. Cancer Inst. 2006, 98, 51–60. [CrossRef] [PubMed]
39. Baecklund, E.; Askling, J.; Rosenquist, R.; Ekborn, A.; Klareskog, L. Rheumatoid arthritis and malignant lymphomas. Curr. Opin. Rheumatol. 2004, 16, 254–261. [CrossRef] [PubMed]
40. Eguchi, K. Apoptosis in Autoimmune Diseases. Intern. Med. 2001, 40, 275–284. [CrossRef] [PubMed]
41. Lyons, S.F.; Liebowitz, D.N. The roles of humans in the pathogenesis of lymphoma. Semin. Oncol. 1998, 25, 461–475. [PubMed]
42. Bhatt, A.S.; Manzo, V.E.; Pedamallu, C.S.; Duke, F.; Cai, D.; Bienfang, D.C.; Padera, R.F.; Docken, W.P. Brief Report: In Search of a Candidate Pathogen for Giant Cell Arteritis: Sequencing-Based Characterization of the Giant Cell Arteritis Microbiome. Arthritis Rheumatol. 2014, 66, 1939–1944. [CrossRef] [PubMed]
43. Fortin, P.R. Vasculitides associated with malignancy. Curr. Opin. Rheumatol. 1996, 8, 30–33. [CrossRef] [PubMed]
44. Solans-Laqué, R.; Bosch-Gil, J.A.; Pérez-Bocanegra, C.; Selva-O’Callaghan, A.; Simeón-Aznar, C.P.; Vilardell-Tarres, M. Paraneoplastic vasculitis in patients with solid tumors: Report of 15 cases. J. Rheumatol. 2008, 35, 294. [PubMed]
45. Baron-Epel, O.; Haviv-Messika, A.; Tamir, D.; Nitzan-Kaluski, D.; Green, M.S. Multiethnic differences in smoking in Israel: Analysis from three national surveys. Eur. J. Public Health 2004, 14, 384–389. [CrossRef] [PubMed]
46. Baron-Epel, O.; Haviv-Messika, A.; Tamir, D.; Nitzan-Kaluski, D.; Green, M.S. Multiethnic differences in smoking in Israel: Analysis from three national surveys. Eur. J. Public Health 2004, 14, 384–389. [CrossRef] [PubMed]